GlassScriptPhysician profile
Alexis Chambers
NPI 1245991504
$2,898.13
in general payments reported to CMS, 2019-2025
27 companies · $2,258 in 2025
The $2,258 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $640 · 2025: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $404.32 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $274.23 | 2024-2025 | |
| Corcept Therapeutics | $238.84 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.86 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $223.36 | 2024-2025 | |
| Amgen INC. | $188.35 | 2024-2025 | Evenity, Prolia, Tepezza |
| Medtronic, INC. | $179.50 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $128.45 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $111.61 | 2024-2025 | Unithroid |
| Lilly USA, LLC | $110.69 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $107.02 | 2025 | |
| Tandem Diabetes Care, INC. | $88.10 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $87.18 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $67.43 | 2024-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $60.53 | 2025 | Flector, Licart, Tirosint |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $60.21 | 2025 | |
| Radius Health, INC. | $56.86 | 2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $49.32 | 2025 | Yorvipath |
| Insulet Corporation | $43.75 | 2025 | Omnipod |
| Verity Pharmaceuticals INC. | $38.05 | 2024-2025 | Tlando |
| Tolmar, INC. | $32.47 | 2024-2025 | Jatenzo |
| Sequel Med Tech, LLC | $29.12 | 2025 | Twiist |
| Kyowa Kirin, INC. | $25.39 | 2025 | |
| Recordati_rare_diseases_inc. | $18.68 | 2025 | Isturisa |
| Madrigal Pharmaceuticals | $18.60 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $16.23 | 2025 | Teriparatide |
| Esperion Therapeutics, INC. | $14.98 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.